#Icad group registration

The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and also will be available on the SECвЂ™s website. A preliminary prospectus supplement relating to the offering was filed with the SEC on Maand is available on the SECвЂ™s website at.

#Icad group registration

333-253808) filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, on March 2, 2021, which registration statement became automatically effective upon filing. 333-235887) previously filed with the Securities and Exchange Commission (вЂњSECвЂќ) on January 10, 2020, which registration statement was declared effective on January 31, 2020, and an additional registration statement on Form S-3MEF (File No. The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes. and Colliers Securities LLC are acting as co-managers for the offering. JMP Securities, Craig-Hallum Capital Group, and Lake Street Capital Markets, LLC are acting as lead managers for the offering and Laidlaw & Company (UK) Ltd. Guggenheim Securities is acting as sole book-running manager for the offering. The closing of the offering is expected to occur on or about March 5, 2021, subject to the satisfaction of customary closing conditions. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 171,516 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds of the offering to the Company are expected to be approximately $22.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. (the вЂњCompanyвЂќ, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of $18.00 per share. NASHUA, N.H., Ma(GLOBE NEWSWIRE) - iCAD, Inc.